转化医学视角下头颈癌人源性肿瘤异种移植瘤模型队列的研究愿景

doi:10.7518/hxkq.2021.06.001

华西口腔医学杂志 ›› 2021, Vol. 39 ›› Issue (6): 617-623.doi: 10.7518/hxkq.2021.06.001

• 专家论坛 • 下一篇

转化医学视角下头颈癌人源性肿瘤异种移植瘤模型队列的研究愿景

张志愿(), 孙树洋

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科，上海交通大学口腔医学院，国家口腔医学中心，国家口腔疾病临床医学研究中心，上海市口腔医学重点实验室，上海 200011

收稿日期:2021-06-09 修回日期:2021-07-27 出版日期:2021-12-01 发布日期:2021-12-03
通讯作者: 张志愿 E-mail:zhzhy0502@163.com
作者简介:张志愿，男，中国工程院院士、医药卫生学部常委，中国医学科学院学部委员。上海交通大学光启讲席教授，主任医师，博士生导师；1998—2014年任上海交通大学医学院附属第九人民医院院长。现任国家级重点学科——口腔医学学科带头人，国家口腔医学中心主任，国家口腔疾病临床医学研究中心主任，上海市口腔医学重点实验室主任，上海市重中之重临床医学中心主任；中华口腔医学会名誉会长、中国抗癌协会常务理事、中国抗癌协会头颈肿瘤专业委员会名誉主委、上海市退（离）休高级专家协会会长；国际牙医学院、英国爱丁堡皇家外科学院和香港大学牙医学院fellowship。受聘为日本大阪齿科大学、空军军医大学客座教授；全国十三五规划教材《口腔颌面外科学》《口腔科学》主编，《上海口腔医学》主编，Frontiers of Oral and Maxillofacial Medicine名誉主编。|长期从事口腔颌面部肿瘤与血管畸形的临床与基础研究。已发表学术论文368篇（SCI收录158篇），尤其近年来完成了国内诱导化疗对中晚期口腔鳞癌前瞻性随机Ⅲ期临床试验，结果发表在J Clin Oncol杂志，连续6年荣列高被引中国学者。主编专著14部、副主编5部和参编专著12部（英文2部），第一负责人承担国家“863”、“十一五”支撑计划，国家自然科学基金重点项目2项、面上项目5项等部、委级课题共20余项；以第一完成人获得国家科学技术进步二等奖2项，国家教学成果奖二等奖、教育部提名国家科学技术奖自然科学奖二等奖等10余项。被评为“卫生部有突出贡献的中青年专家”。曾获何梁何利科学与技术进步奖、全国创新争先奖、全国优秀科技工作者、上海市十大科技精英等，已培养硕、博士研究生75人（国家杰出青年科学基金获得者1人、国家科技部重大研发项目首席科学家1人、中国科学技术协会“托举计划”1人、上海市优秀学科带头人2人、上海市青年科技英才1人、上海市银蛇奖一、二等奖各1人）。张志愿，教授，博士，E-mail：zhzhy0502@163.com
基金资助:
国家重点研发计划(2017YFC0908500);国家自然科学基金重点项目(82030085)

Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives

Zhang Zhiyuan(), Sun Shuyang

Dept. of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai 200011, China

Received:2021-06-09 Revised:2021-07-27 Online:2021-12-01 Published:2021-12-03
Contact: Zhang Zhiyuan E-mail:zhzhy0502@163.com
Supported by:
The National Key Research and Development Program of China(2017YFC0908500);Key Program of National Natural Science Foundation of China(82030085)

摘要/Abstract

摘要：

头颈癌位居全球第七大恶性肿瘤，现存多种治疗策略无法满足大部分患者的临床获益需求。同时，缺乏分子分型指导的头颈癌治疗策略也严重阻碍个性化疗法的发展。近年来，以临床前模型为纽带，加快临床问题与基础成果双向转化的新思路逐渐成为业界共识。PDX模型作为肿瘤基础研究和临床转化的桥梁，能够精准复制肿瘤遗传特征和肿瘤进化，在阐析肿瘤发生发展机制中显示出强大的生命力。借助PDX模型组成的治疗队列，彰显出小鼠为患者进行药物筛选和生物标志物分析的独特优势，这种理想的临床前模型能够在符合伦理范畴内最大可能的为患者寻找潜在的治疗策略。

关键词: 人源性肿瘤异种移植瘤模型, 头颈癌, 异质性, 药物筛选

Abstract:

Head and neck cancer is the seventh common cancer in the world, and various existing treatment strategies provide modest benefit for most patients with head and neck cancer. Meanwhile, therapeutic strategies lacking molecular typing significantly hinder the development of individualized treatment for head and neck cancer. In recent years, connected by preclinical models, the novel ideal has gradually reached a consensus in terms of facilitating inter-transformation of clinical problems and basic achievements. As a bridge between basic research and clinical transformation, patient-derived xenografts (PDX) models precisely replicate genetic characteristics and tumor evolution, which are displaying great vitality in elucidating the mechanism of tumorigenesis and progression. Moreover, cohorts composed of several PDX models highlight the unique advantages of mice for drug screening and biomarker analysis for patients. This ideal preclinical model explores potential treatment strategies suited the ethical standards as much as possible for patients.

Key words: patient-derived xenografts, head and neck cancer, heterogeneity, drug screening

中图分类号:

R 739.8

张志愿, 孙树洋. 转化医学视角下头颈癌人源性肿瘤异种移植瘤模型队列的研究愿景[J]. 华西口腔医学杂志, 2021, 39(6): 617-623.

Zhang Zhiyuan, Sun Shuyang. Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives[J]. West China Journal of Stomatology, 2021, 39(6): 617-623.

参考文献 42

1	Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phaseⅡstudy to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy[J]. J Clin Oncol, 2007, 25(16): 2171-2177.
2	Gillison ML, Trotti AM, Harris J, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019, 393(10166): 40-50.
3	Burtness B, Harrington KJ, Greil R, et al. Pembrolizu-mab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study[J]. Lancet, 2019, 394(10212): 1915-1928.
4	Ma J, Liu Y, Huang XL, et al. Induction chemotherapy decreases the rate of distant metastasis in patients with head and neck squamous cell carcinoma but does not improve survival or locoregional control: a Meta-analysis[J]. Oral Oncol, 2012, 48(11): 1076-1084.
5	Zhong LP, Zhang CP, Ren GX, et al. Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
6	Byrne AT, Alférez DG, Amant F, et al. Interrogating o-pen issues in cancer precision medicine with patient-derived xenografts[J]. Nat Rev Cancer, 2017, 17(4): 254-268.
7	Rygaard J, Povsen CO. Heterotransplantation of a human malignant tumour to “nude” mice. 1969[J]. APMIS, 2007, 115(5): 604-608.
8	Cobb LM. The behaviour of carcinoma of the large bo-wel in man following transplantation into immune depri-ved mice[J]. Br J Cancer, 1973, 28(5): 400-411.
9	Pickard RG, Cobb LM, Steel GG. The growth kinetics of xenografts of human colorectal tumours in immune deprived mice[J]. Br J Cancer, 1975, 31(1): 36-45.
10	Selby PJ, Heyderman E, Gibbs J, et al. A human testicular teratoma serially transplanted in immune-deprived mice[J]. Br J Cancer, 1979, 39(5): 578-583.
11	Fiebig HH, Schuchhardt C, Henss H, et al. Comparison of tumor response in nude mice and in the patients[J]. Behring Inst Mitt, 1984(74): 343-352.
12	Osieka R. Human malignant melanoma: preclinical and clinical drug evaluation[J]. Behring Inst Mitt, 1984(74): 353-367.
13	Shorthouse AJ, Smyth JF, Steel GG, et al. The human tumour xenograft: a valid model in experimental chemotherapy[J]. Br J Surg, 1980, 67(10): 715-722.
14	Giovanella BC, Yim SO, Stehlin JS, et al. Development of invasive tumors in the “nude” mouse after injection of cultured human melanoma cells[J]. J Natl Cancer In-st, 1972, 48(5): 1531-1533.
15	Fogh J, Fogh JM, Orfeo T. One hundred and twenty-se-ven cultured human tumor cell lines producing tumors in nude mice[J]. J Natl Cancer Inst, 1977, 59(1): 221-226.
16	Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials[J]. Br J Cancer, 2001, 84(10): 1424-1431.
17	Daniel VC, Marchionni L, Hierman JS, et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro[J]. Cancer Res, 2009, 69(8): 3364-3373.
18	Dangles-Marie V, Pocard M, Richon S, et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features[J]. Cancer Res, 2007, 67(1): 398-407.
19	Poh A. Novartis compiles mouse avatar “encyclopedia”[J]. Cancer Discov, 2016, 6(1): 5-6.
20	Gao H, Korn JM, Ferretti S, et al. High-throughput s-creening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11): 1318-1325.
21	China plans large center for PDX models[J]. Cancer Discov, 2014, 4(2): 136-137.
22	Ledford H. US cancer institute to overhaul tumour cell lines[J]. Nature, 2016, 530(7591): 391.
23	Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research[J]. Cancer Discov, 2014, 4(9): 998-1013.
24	Stewart EL, Mascaux C, Pham NA, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma[J]. J Clin Oncol, 2015, 33(22): 2472-2480.
25	Lee HW, Lee JI, Lee SJ, et al. Patient-derived xenografts from non-small cell lung cancer brain metastases are va-luable translational platforms for the development of personalized targeted therapy[J]. Clin Cancer Res, 2015, 21(5): 1172-1182.
26	Karamboulas C, Bruce JP, Hope AJ, et al. Patient-derived xenografts for prognostication and personalized treatment for head and neck squamous cell carcinoma[J]. Cell Rep, 2018, 25(5): 1318-1331.e4.
27	McGranahan N, Swanton C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
28	Lilja-Fischer JK, Ulhøi BP, Alsner J, et al. Characterization and radiosensitivity of HPV-related oropharyngeal squamous cell carcinoma patient-derived xenografts[J]. Acta Oncol, 2019, 58(10): 1489-1494.
29	Bi MJ, Zhang Z, Jiang YZ, et al. Enhancer reprogramming driven by high-order assemblies of transcription factors promotes phenotypic plasticity and breast cancer endocrine resistance[J]. Nat Cell Biol, 2020, 22(6): 701-715.
30	Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts (“xeno-patients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer[J]. Cancer Discov, 2011, 1(6): 508-523.
31	Ding L, Ellis MJ, Li SQ, et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft[J]. Nature, 2010, 464(7291): 999-1005.
32	Ben-David U, Ha G, Tseng YY, et al. Patient-derived xenografts undergo mouse-specific tumor evolution[J]. Nat Genet, 2017, 49(11): 1567-1575.
33	Woo XY, Giordano J, Srivastava A, et al. Conservation of copy number profiles during engraftment and passa-ging of patient-derived cancer xenografts[J]. Nat Genet, 2021, 53(1): 86-99.
34	Facompre ND, Rajagopalan P, Sahu V, et al. Identifying predictors of HPV-related head and neck squamous cell carcinoma progression and survival through patient-derived models[J]. Int J Cancer, 2020, 147(11): 3236-3249.
35	Arrowsmith J, Miller P. Trial watch: phaseⅡand phase Ⅲattrition rates 2011-2012[J]. Nat Rev Drug Discov, 2013, 12(8): 569.
36	Hallin J, Engstrom LD, Hargis L, et al. The KRASG12C inhibitor MRTX849 provides insight toward therapeutic susceptibility of KRAS-mutant cancers in mouse models and patients[J]. Cancer Discov, 2020, 10(1): 54-71.
37	Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds[J]. Cell, 2016, 167(1): 260-274.e22.
38	Zhou R, Shi CJ, Tao WJ, et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations[J]. Clin Cancer Res, 2019, 25(12): 3548-3560.
39	韩永. Ponatinib靶向抑制c-kit突变的头颈黏膜恶性黑色素瘤的实验研究[D]. 上海: 上海交通大学, 2017.
	Han Y. Ponatinib effectively inhibits c-kit mutations in patient derived tumor model of mucosal melanoma of head and neck[D]. Shanghai: Shanghai Jiao Tong University, 2017.
40	Mosier DE, Gulizia RJ, Baird SM, et al. Transfer of a functional human immune system to mice with severe combined immunodeficiency[J]. Nature, 1988, 335(6187): 256-259.
41	McCune JM, Namikawa R, Kaneshima H, et al. The S-CID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function[J]. Scien-ce, 1988, 241(4873): 1632-1639.
42	Doulatov S, Notta F, Laurenti E, et al. Hematopoiesis: a human perspective[J]. Cell Stem Cell, 2012, 10(2): 120-136.

[1]	唐洪杨凯赵成白云龙黄昊. 近红外荧光量子点表皮生长因子受体单克隆抗体探针对头颈部鳞状细胞癌活体可视化成像和体内分布的动物实验研究[J]. 华西口腔医学杂志, 2012, 30(6): 568-573.
[2]	孙坚　张志愿　叶为民　李军　邱蔚六. 头颈癌累及颈动脉的切除与重建[J]. 华西口腔医学杂志, 2002, 20(01): 24-26.

转化医学视角下头颈癌人源性肿瘤异种移植瘤模型队列的研究愿景

Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 42

相关文章 2

编辑推荐

Metrics

本文评价